Sign in

    Kallum Lewis Titchmarsh

    Stock Analyst at Morgan Stanley

    Kallum Lewis Titchmarsh is a Stock Analyst at Morgan Stanley, focused on the healthcare sector, particularly medical device companies such as Penumbra and Inspire Medical Systems. Despite a limited track record with only 5 published ratings, his calls have demonstrated a 16.67% success rate and a low average return, ranking 4,610 out of 4,619 analysts by performance. Titchmarsh began issuing official research in 2024 and has maintained coverage on Penumbra with notable price target updates, while also providing ratings for Inspire Medical Systems. His professional credentials and securities licenses are not publicly documented, and no notable industry recognition or awards are currently associated with his profile.

    Kallum Lewis Titchmarsh's questions to SI-BONE (SIBN) leadership

    Kallum Lewis Titchmarsh's questions to SI-BONE (SIBN) leadership • Q4 2024

    Question

    Kallum Lewis Titchmarsh asked if SI-BONE could benefit from sales force disruption at competitors, how the company plans to achieve its rep productivity targets, and requested any new details on the ongoing DOJ investigation.

    Answer

    CEO Laura Francis confirmed that industry disruption presents an opportunity to hire top talent and detailed that rep productivity gains to over $2 million will come from a combination of direct reps, junior rep promotions, and the hybrid agent model. Regarding the DOJ inquiry, she stated there are no material updates, reiterated cooperation, and noted the government's focus appears to be on field-based education events and physician remuneration.

    Ask Fintool Equity Research AI